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 29 
Abstract 30 
Olfactory dysfunction is one of the earliest features in Lewy-type alpha-31 
synucleinopathies (LTS) such as Parkinson´s disease (PD). However, the underlying 32 
molecular mechanisms associated to smell impairment are poorly understood. Applying 33 
mass spectrometry-based quantitative proteomics in postmortem olfactory bulbs (OB) 34 
across limbic, early-neocortical, and neocortical LTS stages of parkinsonian subjects, a 35 
proteostasis impairment was observed, identifying 268 differentially expressed proteins 36 
between controls and PD phenotypes. In addition, network-driven proteomics revealed a 37 
modulation in ERK1/2, MKK3/6, and PDK1/PKC signalling axis. Moreover, a cross-38 
disease study of selected olfactory molecules in sporadic Alzheimer’s disease (AD) 39 
cases, revealed different protein derangements in the modulation of Secretagogin 40 
(SCGN), Calcyclin binding protein (CACYBP), and Glucosamine 6 phosphate 41 
isomerase 2 (GNPDA2) between PD and AD. An inverse correlation between GNPDA2 42 
and α-synuclein protein levels was also reflected in PD cerebrospinal fluid (CSF). 43 
Interestingly, PD patients exhibited significantly lower serum GNPDA2 levels than 44 
controls (n=82/group). Our study provides important avenues for understanding the OB 45 
proteostasis imbalance in PD, deciphering mechanistic clues to the equivalent smell 46 
deficits observed in AD and PD pathologies.  47 
Keywords: Parkinson’s disease, Olfactory bulb, Proteomics, Systems Biology 48 
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Abbreviations 54 
AD: Alzheimer´s disease 55 
CACYBP: Calcyclin binding protein 56 
CPNE6: Copine-6 57 
DPP6: Dipeptidyl aminopeptidase-like protein 6 58 
GNPDA2: Glucosamine 6 phosphate isomerase 2 59 
LBD: Lewy body disease 60 
LTS: Lewy-type alpha-synucleinopathy 61 
OB: olfactory bulb 62 
PD: Parkinson´s disease 63 
RACK1: Receptor of activated protein C kinase 1 64 
SCGN: secretagogin 65 
 66 
1. Introduction 67 
Olfactory dysfunction is present in up to 95% of PD patients (Attems et al., 2014; Doty, 68 
2012b). In Lewy body diseases (LBDs), including PD, the olfactory deficit is an early 69 
prodromal event being considered as a premotor sign of neurodegeneration (Baba et al., 70 
2012; Beach et al., 2009; Doty, 2008, 2012b). The initial induction of α-synuclein 71 
misfolding and subsequent deposition, probably occurs in the olfactory bulb (OB) 72 
and/or the enteric nervous system (Klingelhoefer and Reichmann, 2015; Rey et al., 73 
2016). Clinical features of olfactory dysfunction have been correlated with the presence 74 
of Lewy-type alpha-synucleopathy (LTS) in different olfactory areas (Attems et al., 75 
2014; Beach et al., 2009; Saito et al., 2016; Ubeda-Banon et al., 2010a; Ubeda-Banon et 76 
al., 2012; Ubeda-Banon et al., 2010b). Furthermore, microstructural white matter 77 
reductions in the olfactory system, the reduction of the cholinergic centrifugal inputs to 78 
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the OB, and the increased number of the dopaminergic cells observed in the OB, have 79 
also been suggested as potential origins of smell loss (Ibarretxe-Bilbao et al., 2010; 80 
Mundinano et al., 2011; Mundinano et al., 2013).  81 
PD and Dementia with Lewy bodies (DLB) are Lewy body diseases (LBD) because of 82 
the presence of typical intracytoplasmic neuronal inclusions named Lewy bodies (LB) 83 
together with Lewy neurites containing abnormal α-synuclein. Systematic study of 84 
cases with LB pathology has prompted a staging classification of PD (and LBDs) from 85 
the medulla oblongata and OB to the midbrain, diencephalic nuclei, and neocortex 86 
(Braak et al., 2002; Braak et al., 2003; Braak et al., 2004). Stages 1, 2, 3 reflect, 87 
respectively, LB pathology in the medulla oblongata, pons and midbrain; stage 4 88 
includes, in addition, the basal prosencephalon and mesocortex; stage 5 extends to 89 
sensory association areas of the neocortex and prefrontal neocortex; and stage 6 90 
includes, in addition, lesions in first order sensory association areas of the neocortex and 91 
pre-motor areas(Braak et al., 2002; Braak et al., 2003; Braak et al., 2004). Similar 92 
categorization of LB pathology was used to classify DLB (McKeith et al., 2017; 93 
McKeith et al., 2005; McKeith et al., 1996). The later classification covers three stages: 94 
brain stem, limbic and neocortical. Atypical cases not following a clear gradient of LB 95 
pathology from the lower brain stem and olfactory regions to the neocortex constitute 96 
about ten percent of total LBDs (Braak et al., 2006; Jellinger, 2008, 2009). The most 97 
frequent atypical LBD is the amygdala-predominant which was added as a peculiar 98 
form to the former LBD-brain stem, LBD-limbic and LBD-neocortical classification 99 
(Leverenz et al., 2008). All these classifications are based on the putative progression 100 
with time of LB pathology in the brain from the medulla oblongata and OB to the 101 
neocortex. Neuropathological studies have pointed out that the presence and severity of 102 
α-synuclein pathology in the OB reflects the presence and severity of synucleinopathy 103 
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in other brain regions (Attems et al., 2014; Beach et al., 2009). Some studies have 104 
demonstrated that the presence of LTS in the OB predicts with 90% sensitivity and 105 
specificity the existence of neuropathologically confirmed PD (Beach et al., 2009). 106 
Moreover, the sensitivity and specificity of clinical olfactory testing in differentiating 107 
PD from non-PD ranges from 80% to 100% (Doty, 2012a). In addition, an OB atrophy 108 
and a significant reduction in olfactory performance have been detected in PD respect to 109 
control subjects (Brodoehl et al., 2012; Li et al., 2016). In view of these clinical and 110 
neuropathological data, an in depth molecular characterization of the OB 111 
neurodegeneration is necessary to reveal the missing links in the biochemical 112 
understanding of the early smell impairment in PD.  113 
In this work, we applied mass-spectrometry based quantitative proteomics as a 114 
discovery platform to explore the magnitude and chronology of the OB proteome 115 
modulation across limbic, early-neocortical, and neocortical LTS stages in PD cases, 116 
also named LBD-limbic stage, LBD-early neocortical stage, and LBD neocortical stage. 117 
First, we have used a novel technique, called MALDI-IMS, or MALDI - Imaging. The 118 
use of MALDI-IMS offers the great advantage to investigate the physiopathological 119 
changes taking place directly in tissue while retaining the histopathological context, 120 
enabling the so-called “Molecular Histology” (Caprioli et al., 1997; Chaurand et al., 121 
2004). Second, we have applied a label-free shotgun proteomic approach getting more 122 
than 250 differential expressed proteins between controls and PD-related phenotypes, 123 
pinpointing specific pathways, protein interaction networks, and potential novel 124 
therapeutic targets. 125 
2. Materials and methods  126 
2.1 Materials - The following reagents and materials were used: anti-GAPDH 127 
(Calbiochem), anti-MKK3, anti-MKK6, anti-phospho MKK3 (Ser189)/MKK6 128 
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(Ser207), anti-p38 MAP kinase, anti-phospho p38 MAP kinase (Thr180/Tyr 182), anti-129 
p38 MAPK alpha, anti-p38 MAPK beta, anti-PDK1, anti-phospho PDK1 (S241), anti-130 
PKC-Pan, anti-phospho PKC-pan (T514), anti-pAkt (Ser473), anti-Akt, anti-pERK1/2 131 
(Thr202/Tyr204), anti-ERK1/2 and anti-CACYBP (Cell Signaling), anti-CPNE6 132 
(Thermo), anti-GNPDA2, anti-NEGR1, anti-RACK1, anti-SCGN (Abcam), anti-α-133 
synuclein (Santa Cruz Biotech), and anti-DPP6 (Sigma).  Electrophoresis reagents were 134 
purchased from Bio-rad and trypsin from Promega. 135 
2.2 Human samples – According to the Spanish Law 14/2007 of Biomedical Research, 136 
inform written consent forms were obtained for research purposes from relatives of 137 
patients included in this study. The study was conducted in accordance with the 138 
Declaration of Helsinki and all assessments, post-mortem evaluations, and procedures 139 
were previously approved by the Clinical Ethics Committee of Navarra Health Service. 140 
OB specimens (table 1), CSF samples (additional file 7) and associated clinical and 141 
neuropathological data from PD subjects were supplied by the Parkinson's UK Brain 142 
Bank, funded by Parkinson's UK, a charity registered in England and Wales (258197) 143 
and in Scotland (SC037554), and the Neurological Tissue Bank from Navarrabiomed 144 
(Pamplona, Spain). Neuropathological assessment was performed according to 145 
standardized neuropathological scoring/grading systems (Alafuzoff et al., 2009). 146 
Twenty-one PD cases were distributed into: LBD-limbic stage (LBDL) (n=7), LBD-147 
early neocortical stage (LBDE) (n=6), and LBD-neocortical stage (LBDN) (n=8). Eight 148 
cases from elderly subjects with no history or histological findings of any neurological 149 
disease were used as a control group. For validation and specificity analysis, OB 150 
specimens and associated neuropathological data from AD subjects (n=14), were 151 
supplied by the Neurological Tissue Bank of the Biobank from the Hospital Clinic-152 
Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), and the 153 
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Neurological Tissue Bank of HUB-ICO-IDIBELL (Barcelona, Spain). All human brains 154 
considered in this study (n=43) had a post-mortem interval (PMI) lower than 26 hours 155 
(Table 1). Serum samples and data from patients included in the study were provided by 156 
the Biobank of the University of Navarra and were processed following standard 157 
operating procedures approved by the Ethical and Scientific Committees (Additional 158 
file 1). 159 
2.3 MALDI imaging mass spectrometry (IMS) - OBs from three different conditions 160 
were washed with PBS and immediately frozen and stored at − 80 °C until analyzed in 161 
order to preserve the native tissue morphology and minimize protein degradation. 162 
Sample tissues were sectioned at 14 μm using a Leica RM2235 cryostat (Leica, 163 
Wetzlar, DE) and thaw-mounted on ITO-coated glass slides (Bruker Daltonics, Bremen, 164 
DE) for mass spectrometry (MS) analysis, following previously published protocols 165 
(Lloro et al., 2017; Mourino-Alvarez et al., 2016).  166 
2.4 Sample preparation for shotgun proteomics - OB specimens derived from control 167 
and PD cases were homogenized in lysis buffer containing 7 M urea, 2 M thiourea, 4% 168 
(w/v) CHAPS, 50 mM DTT. The homogenates were spinned down at 100.000 x g for 1 169 
h at 15°C. Prior to proteomic analysis, protein extracts were precipitated with 170 
methanol/choloroform, and pellets dissolved in 6M Urea, Tris 100mM pH 7.8. Protein 171 
quantitation was performed with the Bradford assay kit (Bio-Rad). 172 
2.5 Label free LC-MS/MS –Protein enzymatic cleavage (10ug) was carried out with 173 
trypsin (Promega; 1:20, w/w) at 37°C for 16 h as previously described (Shevchenko et 174 
al., 2006). Peptides mixtures were separated by reverse phase chromatography using an 175 
Eksigent nanoLC ultra 2D pump fitted with a 75 μm ID column (Eksigent 0.075 x 250). 176 
Samples were first loaded for desalting and concentration into a 0.5 cm length 100 μm 177 
ID precolumn packed with the same chemistry as the separating column. Mobile phases 178 
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were 100% water 0.1% formic acid (FA) (buffer A) and 100% Acetonitrile 0.1% FA 179 
(buffer B). Column gradient was developed in a 240 min two step gradient from 5% B 180 
to 25% B in 210 min and 25%B to 40% B in 30 min. Eluting peptides were analyzed 181 
using a 5600 Triple-TOF system, as previously described (Lachen-Montes et al., 2017).  182 
2.6 Peptide Identification and Quantification – MS/MS data acquisition, searching, 183 
peptide quantitation, and statistical analysis were performed as previously described 184 
(Lachen-Montes et al., 2017). MS raw data and search results files have been deposited 185 
to the ProteomeXchange Consortium (http://proteomecentral.proteomexchange.org) via 186 
the PRIDE partner repository (Vizcaino et al., 2014) with the dataset identifiers 187 
PXD008036.  188 
2.7 Statistical analysis - The statistical analysis used for the identification of 189 
differentially expressed proteins was performed using the Progenesis software and R 190 
scripts. Before applying any statistical test, data were submitted to several mathematical 191 
algorithms to remove the background, to align and compensate the ‘’between-run 192 
variation’’, and to choose the same peaks in all samples in the peak picking phase. 193 
Then, peptides were identified with the information obtained using Protein Pilot 194 
software. Output files with the identified proteins were then managed with R scripts for 195 
subsequent statistical analysis. One-way ANOVA test was applied to compare the 196 
results between all groups and unpaired Student’s t-test was used for direct comparisons 197 
between two groups of samples. Statistical significance was set at p<0.05 in all cases 198 
and 1% peptide FDR (False discovery rate) threshold was considered (calculated based 199 
on the search results against a decoy database).  Additionally, an absolute fold change 200 
of <0.77 (down-regulation) or >1.3 (up-regulation) in linear scale was considered to be 201 
significantly differentially expressed. Concerning the immunoassays, the comparison 202 
made between the neuropathological groups and the neurological intact control group 203 
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was performed using the unpaired T test for independent samples.  A p value <0.05 was 204 
considered significant. Results are represented as mean ± SE and errors bars show the 205 
standard error of the mean from the samples used in each group.  206 
2.8 Bioinformatics –The proteomic information was analyzed using Reactome (Fabregat 207 
et al., 2018) in order to detect and infer differentially activated/deactivated pathways as 208 
a result of PD phenotypes. The identification of specifically dysregulated 209 
regulatory/metabolic networks across PD stages was analysed through the use of 210 
QIAGEN’s Ingenuity® Pathway Analysis (IPA) (QIAGEN Redwood City, 211 
www.qiagen.com/ingenuity).  212 
 2.9 Immunoblotting analysis - In the case of CSF samples, 100-150μl were precipitated 213 
with four volumes of acetone o/n at -20ºC. Then, samples were centrifuged during 15 214 
minutes at 14000rpm to obtain the protein pellet. Equal amounts of OB protein (10 μg) 215 
or CSF protein (8 μg) were resolved in 4-15% TGX stain-Free gels (Bio-Rad). Western-216 
blot analysis were performed as previously described (Lachen-Montes et al., 2017). 217 
After densitometric analyses (Image Lab Software Version 5.2; Bio-Rad), optical 218 
density values were expressed as arbitrary units and normalized to GAPDH (tissue 219 
analysis) or to total stain in each gel lane (CSF analysis) (Moritz, 2017). 220 
2.10 Enzyme-Linked Immunosorbent Assay. Serum GNPDA2 concentrations were 221 
measured using enzyme-linked immunosorbent assay (ELISA) kits according to the 222 
manufacturer’s instructions (MBS93411798; MyBiosource). The detection range was 223 
0.62 ng/ml – 20 ng/ml. Data were analyzed using Graphpad Prism software. Mann–224 
Whitney U test was used for between-group comparisons. We considered p-value less 225 
than 0.05 to be statistically significant. 226 
Results 227 
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3.1 Proteostasis impairment in the OB across Lewy-type alpha-synucleinopathy (LTS) 228 
staging  229 
In this work, we combined two complementary mass spectrometry-based proteomic 230 
approaches such as MALDI-IMS and label-free quantitative proteomics to probe 231 
additional molecular disturbances in post-mortem OBs dissected from clinically 232 
confirmed PD cases respect to neurologically intact controls. First, MALDI-IMS was 233 
applied for the first time in OB region to visualize in situ additional molecular 234 
disturbances between control and LB neuropathological stages (Figure 1). Several 235 
masses with differential spatial distribution between control and LB stages have been 236 
found with ROC (Receiving Operating Characteristic) curves with statistical 237 
significance (Area Under the Curve (AUC) >0.8). To determine and characterize the 238 
progression and complexity of LTS-associated changes in this olfactory structure, the 239 
OB site-specific proteomic signature was monitored across LTS staging using a 240 
complementary label-free MS-based approach. Among 1629 quantified proteins across 241 
all experimental groups, 268 proteins tend to be differentially expressed between 242 
controls and PD phenotypes (Fig.2A and additional file 2). A progressive increment in 243 
OB monomeric α-synuclein protein levels was also evidenced across LTS stages by 244 
Western-blot (Fig.2B). Our analysis revealed that 148, 139, and 197 OB proteins are 245 
differentially expressed in LBDL, LBDE, and LBDN stages, respectively. The 246 
distribution between up-regulated and down-regulated proteins was very similar across 247 
LTS grading (35-40% down-regulated, and 60-65% up-regulated proteins) (Fig. 2C). 248 
Interestingly, 65 OB proteins overlapped between all stages (Fig. 2D), suggesting a 249 
potential role during LTS progression in PD subjects. Most of these proteins mainly 250 
clustered in specific biological process like transport and RNA processing with specific 251 
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molecular functions such as nucleotide binding and hydrolase activities (Additional file 252 
3). 253 
3.2 Olfactory dysregulated pathways across LTS grading 254 
To extract biological knowledge, the differential OB proteome detected in each LTS 255 
stage, was functionally categorized (Additional file 4). Immune system, metabolism of 256 
lipids, aminoacids, and carbohydrates, signaling by growth factors and specific survival 257 
pathways, together with vesicle-mediated transport and axon guidance were the 258 
common over-represented dysregulated processes across LTS grading (Additional file 259 
5A). To gain a more detailed description of the molecular mechanisms involved in the 260 
OB during LB pathology, subsequent analyses were performed to explore the 261 
differential olfactory proteome distributions across specific neuronal functionalities. As 262 
shown in additional file 5B, our results point out a deregulation of specific protein 263 
clusters related to cell death, basal ganglia dysfunction, and movement disorders. 264 
Specifically, proteins involved in dyskinesia and tremor were exclusively mapped in 265 
LBDN stage (Additional file 6). To characterize, in detail, the potential dysregulation of 266 
LTS-related protein interactomes in the OB during the neurodegenerative process, we 267 
have performed proteome-scale interaction networks merging the olfactory proteins that 268 
tend to be deregulated in each LTS stage. Using IPA software, protein interactome maps 269 
has been constructed for each LTS stage (Figure 3). In LBDL stage, the functional 270 
interaction network indicated an alteration in HNRNP complexes (HNRNPA2B1, 271 
HNRNPM, HNRNPC, HNRNPH3, HNRNPR), RNA binding proteins (ILF2, MATR3, 272 
DDX6), as well as transcriptional and translational repressors (XRCC5, RACK1, 273 
RUVBL1) suggesting an impairment in RNA stability and pre-mRNA splicing 274 
processes (Figure 3A). In LBDE stage, the proteome-scale interaction network reflected 275 
an alteration in multiple interactors of nucleophosmin (NPM1), reinforcing the 276 
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transcriptional derangements that occur at the level of the OB (Figure 3B). The 277 
functional clustering also suggested an imbalance in signaling molecules involved in 278 
cell survival and differentiation such as CSNK2B, LIMS1, and PP2A (Figure 3B). In 279 
LBDN stage, functional interactors of specific survival routes were compromised, 280 
suggesting an imbalance in the survival potential of olfactory neurons (Figure 3C).  281 
3.3 Network-driven proteomics reveals olfactory derangements in survival pathways 282 
in Parkinson´s disease 283 
Signaling modulators like ERK, Akt, CaMKII, PKC and p38 MAPK appeared as 284 
principal nodes in protein interactome maps (figure 3). Subsequent experiments were 285 
performed to monitor the activation state of this kinase panel across LTS staging. 286 
Respect to MAPK pathway, a significant increment in the steady-state levels of MEK 287 
was observed in LBDN stage. On the contrary, a progressive down-regulation of ERK 288 
levels was evidenced across LTS staging (figure 4A). Phosphoinositide-dependent 289 
protein kinase 1 (PDK1) activity depends on the autophosphorylation on Ser241, 290 
activating PKC signal transduction (Mora et al., 2004). Despite the up-regulation in 291 
total PDK1 levels observed in LBDL stage, PDK1 was inactivated across LBDE and 292 
LBDN stages (figure 4B). Moreover, PDK1 inactivation was accompanied by a 293 
decrease in the activation status of PKC isoforms in LBDE stage, as revealed by 294 
Western-blot using a specific pan-antibody against phosphorylated PKC isoforms 295 
(Figure 4B). MKK3 and MKK6 are dual-specificity protein kinases that activate p38 296 
MAPK (Derijard et al., 1995). We evaluated the activation state of olfactory MKK3-297 
6/p38 MAPK axis across LTS staging. As shown in figure 4C, MKK3/6 were 298 
significantly inactivated across all stages, mainly due to a drop in total MKK6 levels. 299 
On the other hand, no significant changes were observed in the activation state of p38 300 
MAPK, detecting an over-expression of p38-alpha and -beta subunits in LBDL stage, 301 
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and a specific increment of p38-alpha protein in LBDN stage (Figure 4C). These data 302 
suggest the existence of upstream disruption of olfactory MAPK, PDK1/PKC, and 303 
MKK3-6/p38 MAPK axis among neuropathological stages. On the other hand, a 304 
slightly increment in the activation state of Akt and CaMKII was observed in LBDL 305 
stage, although these changes were not statistically significant (Figure 4D). 306 
3.4 Searching common pathological olfactory substrates in AD and PD phenotypes 307 
It has been recently proposed the potential existence of common olfactory pathological 308 
substrates in AD and PD, mainly due to the equivalent severe olfactory deficits present 309 
at earliest stages of both neurological syndromes (Doty, 2012b, 2017). With the aim to 310 
identify common olfactory protein intermediates deregulated in both neurodegenerative 311 
backgrounds, a cross-disease study of selected olfactory molecules was performed in 312 
sporadic AD cases. For that, OB samples derived from low (Braak I-II), intermediate 313 
(Braak III-IV), and high AD (Braak V-VI) were included in the cross-disease study 314 
(Table 1). The selection of assessing the protein panel for verification was based 315 
primarily on: i) differential expression across LTS stages and novelty in human PD 316 
pathophysiology (SCGN, CACYBP, GNPDA2, RACK1) and ii) differential expression 317 
in the OB from different neurological disorders (CPNE6, and DPP6) (Zelaya et al., 318 
2015). Our group has previously identified CPNE6 (Copine-6) and DPP6 (Dipeptidyl 319 
aminopeptidase-like protein 6) as olfactory protein mediators deregulated in specific 320 
neurological syndromes (Zelaya et al., 2015). As shown in figure 4E, olfactory CPNE6 321 
and DPP6 protein levels were significantly increased in LBDL and LBDN stages. 322 
SCGN (Secretagogin) is a calcium binding protein considered marker of periglomerular 323 
and deep-layer olfactory interneurons (Attems et al., 2012). CACYBP (Calcyclin 324 
binding protein) is involved in cytoskeletal dynamics and in the regulation of 325 
transcriptional responses in neurons (Filipek et al., 2008; Kilanczyk et al., 2015). 326 
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GNPDA2 (Glucosamine 6 phosphate isomerase 2) participates in the glucose 327 
metabolism, converting D-glucosamine-6-phosphate into D-fructose-6-phosphate and 328 
ammonium (Arreola et al., 2003). RACK1 (Receptor of activated protein C kinase 1) 329 
protects neurons from oxidative-stress-induced apoptosis (Ma et al., 2014). First, and 330 
with the aim to complement and partially validate our proteomic workflow, the steady-331 
state levels of our protein panel were checked across LTS staging by Western blotting. 332 
In accordance with our proteomic findings, the immunoblots confirmed the olfactory 333 
over-expression of SCGN, GNPDA2, and RACK1 across LTS stages (Figure 4F). In 334 
addition, a significant down-regulation of CACYBP was observed in LBDE, and LBDN 335 
stages (Figure 4F). The monitorization of the expression of our protein panel in the OB 336 
from AD cases (Figure 5A) revealed that: i) SCGN protein levels were down-regulated 337 
in the OB derived from high AD cases, ii) CACYBP was specifically over-expressed in 338 
low AD cases, iii) a significant increment in OB GNPDA2 protein levels across low and 339 
intermediate AD, iv) no significant changes in OB RACK1 were observed across AD 340 
staging. This cross-disease analysis revealed the existence of common protein 341 
intermediates that are differentially deregulated during PD and AD progression at the 342 
level of the OB. 343 
3.5 GNPDA2 protein biofluid profile differs between controls and PD subjects 344 
We further examined whether our protein panel could be detected in the CSF of PD 345 
subjects and ultimately serves as potential novel PD biomarkers. Interestingly, 346 
GNPDA2 was previously characterized by mass-spectrometry in CSF (Guldbrandsen et 347 
al., 2014). Subsequent experiments were performed to check the GNPDA2 expression 348 
in the CSF of PD patients (n=16) and healthy control subjects (n=9) (Additional file 7) 349 
by Western-blot analysis. As shown in figure 5B, GNPDA2 protein levels were 350 
significantly increased in CSF from PD patients respect to controls, showing an inverse 351 
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correlation between GNPDA2 and α -synuclein protein levels detected in CSF. 352 
However, serum GNPDA2 levels were decreased in PD population (Figure 6) 353 
(Additional file 1), suggesting that the GNPDA2 profiles observed in both biofluids 354 
may be a consequence of the damaged blood-brain barrier (BBB) previously observed 355 
in PD (Sweeney et al., 2018).  356 
4. Discussion 357 
In view of the general recognition that olfactory dysfunction is an early feature of PD, 358 
we consider that the elucidation of the progressive proteome-wide alterations that 359 
occurs in the OB, might provide novel candidate proteins for a druggability assessment 360 
in PD. Neuroproteomics has been successfully applied to discover novel protein 361 
mediators associated with PD pathogenesis, diagnosis and evolution (Jin et al., 2006; 362 
Lehnert et al., 2012; Licker et al., 2012; Licker et al., 2014; Liu et al., 2015). To our 363 
knowledge, this is the first study to characterize potential PD-associated molecular 364 
changes in the human OB combining imaging mass-spectrometry and quantitative 365 
proteomics. In a first approach, using MALDI-IMS as a molecular histology technique, 366 
we have observed that there are obvious molecular changes between control and LB 367 
stages, at protein level, with several distinctive masses (ROC curves with AUC values 368 
>0.8) adopting marked positional domains in LB stages. Our data suggest that MALDI-369 
IMS is a suitable approach that complements current neuropathological classifications. 370 
Some of the differential expressed OB proteins detected across LTS stages have been 371 
proposed as α-synuclein interactors or protein components of Lewy body inclusions 372 
(Betzer et al., 2015; Leverenz et al., 2007): IGSF8 (in LBDL stage), GNAO1, OMG, 373 
ARPC5, and NIPSNAP1 (in LBDE stage), HSD17B10, ATP6V1D, PGRMC1, 374 
ACADS, and TUBB2 (in LBDN stage), VPS53 (common to LBDL and LBDE stages), 375 
ATP1A2, EHD1, EEF1A2, and BANF1 (common to LBDE and LBDN stages), and 376 
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TUBB4A, TPPP, and TUBA4A (common to all stages). To establish a functional 377 
relationship between the OB and other PD-affected regions at proteome level, a 378 
traceability analysis was performed comparing the differential OB protein set with 379 
respect to deregulated proteins previously detected in functionally related structures 380 
such as SN, striatum, and cortex derived from PD subjects (Licker et al., 2014; Riley et 381 
al., 2014). In accordance with down-regulated OB proteome, the expression of five 382 
nigral proteins, three cortical proteins, and striatal protein OMG were also down-383 
modulated in PD. In contrast, nigral protein MYO6, fourteen striatal proteins, and 384 
eighteen cortical proteins present an opposite expression pattern (up-regulation) in PD 385 
subjects (Additional file 8). With respect to the up-regulated OB proteome, four nigral 386 
proteins, twenty striatal proteins, and seventeen cortical proteins were also up-regulated 387 
in PD phenotypes (Additional file 8). This information suggests that the coordinated 388 
deregulation of specific protein modules shared among brain areas might explain, in 389 
part, the existence of conserved transcriptional programs that may be 390 
activated/deactivated across structures during PD pathogenesis.  391 
The aberrant regulation of a subset of kinases may represent the triggering events 392 
leading to the spread of an abnormal signaling in PD (Wang et al., 2012). In this 393 
context, cell survival mechanisms have been proposed as targets for neuroprotective 394 
strategies in delay onset, or slow progression of PD (Goswami et al., 2017). Analyzing 395 
the signaling interactions predicted by our network-system biology approach, we 396 
determine potential upstream regulators highly interconnected with deregulated 397 
olfactory proteins. An increment in phospho-ERK levels has been previously reported 398 
in midbrain dopaminergic neurons in PD brains (Zhu et al., 2003; Zhu et al., 2002). 399 
However, in leukocytes, ERK1/2 activity does not significantly differ between controls 400 
and PD subjects (White et al., 2007). In our case, the activation of the pro-survival 401 
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factor ERK1/2 tends to be compromised across LTS stages. Interestingly, a 402 
hyperactivation of upstream MEK1/2 and ERK1/2 was evidenced in the OB derived 403 
from AD subjects (Lachen-Montes et al., 2016), suggesting that MAPK signalling 404 
clearly differs between PD and AD phenotypes at olfactory level.  It has been shown 405 
that p38 MAPK is activated by α-synuclein (Rannikko et al., 2015), being localized in 406 
neurons of PD brain stem bearing LBs or α-synuclein deposits (Ferrer et al., 2001). An 407 
early inactivation of MKK3/6-p38 MAPK axis has been observed in initial AD stages at 408 
OB level, recovering normal levels in intermediate and advanced AD stages (Lachen-409 
Montes et al., 2017). However, a distinct profile was observed in PD phenotypes. The 410 
inactivation of MKK3/6 across LTS stages suggests the involvement of other kinase-411 
based route in the apparent maintenance of olfactory p38 MAPK activity in the OB 412 
from PD. To our knowledge, our data represent the first molecular link between PDK1 413 
dysregulation and PD. An impairment of olfactory PDK1/PKC signaling axis was 414 
observed in LBDL and LBDE stages. Interestingly, and in line with these findings, this 415 
pathway is also modified in the OB of AD subjects (Lachen-Montes et al., 2017). As α-416 
synuclein specifically downregulates PKCδ isoform in dopaminergic cells (Jin et al., 417 
2011), further work will be necessary to clarify the specific role of each PKC isoform in 418 
olfactory neurons during PD progression.  419 
Although the activation state of specific olfactory survival pathways differs between PD 420 
and AD, this study has allowed the identification of a subset of common protein 421 
intermediates in the OB from PD and AD subjects respect to non-demented controls, 422 
suggesting that these shared proteins might participate as common pathological 423 
substrates during the olfactory neurodegenerative process in both neurological disorders 424 
(Doty, 2012b, 2017). However, it is important to note that 14 out of 21 (67%) PD 425 
subjects included in our study, present concomitant AD-type Tau pathology (Braak 426 
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stage I-II) (data not shown). Said that, we cannot exclude the possibility that the shared 427 
differential OB proteome observed between AD and PD may be due to the AD 428 
concomitant pathology present in PD subjects. In the present study, novel common 429 
mediators have emerged but with different expression profiling between PD and AD 430 
phenotypes, emphasizing the importance of neuropathological stage-dependent analysis 431 
in the search of potential olfactory therapeutic targets. CPN6, and DPP6 tend to be up-432 
regulated in the OB from PD subjects, indicating specific differences in spine plasticity 433 
and synaptic function (Lin et al., 2013; Reinhard et al., 2016) respect to AD (Zelaya et 434 
al., 2015). Moreover, the different expression profile observed between AD and LTS 435 
stages for SCGN, CACYBP, and RACK1 proteins also points out subtle differences in 436 
calcium fluxes, cytoskeletal dynamics, and oxidative response in the OB from AD and 437 
PD subjects. Interestingly, the metabolic enzyme GNPDA2 was over-expressed in most 438 
PD and AD cases (see also additional file 9B), showing an inverse correlation between 439 
GNPDA2 and α-synuclein protein levels in the CSF from PD subjects. However, serum 440 
GNPDA2 levels were significantly decreased in PD population. The different protein 441 
profile across fluids has been also observed for other proteins in the context of PD such 442 
as Complement C4, serotransferrin, apolipoprotein AI, haptoglobin, zinc-alpha-2-443 
glycoprotein, Apolipoprotein E, beta-2-glycoprotein, ceruloplasmin, complement C3 444 
and serum albumin (Halbgebauer et al., 2016). The lack of standardization between 445 
laboratories in CSF collection and preparation procedures may be a reason for this type 446 
of observation. However, from a biological point of view, these molecular events may 447 
be due to the damage of the blood-brain barrier (BBB) observed in PD subjects 448 
(Alexander et al., 1994; Kortekaas et al., 2005; Sweeney et al., 2018). Checking the 449 
Human Protein Atlas (Uhlen et al., 2010)(www.proteinatlas.org), GNPDA2 is highly 450 
expressed by the brain (https://www.proteinatlas.org/ENSG00000163281-451 
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GNPDA2/tissue), so additional experiments are needed to explain the GNPDA2 efflux, 452 
rates, and transportation (both the brain-to-blood and the blood-to-brain directions) in 453 
the PD pathophysiology. Being aware of the small number of cases assessed in this 454 
study, the novel relation of secreted GNPDA2, and α-synuclein should be further 455 
evaluated in combination with other biochemical markers in order to improve the 456 
current diagnostic assays (Eusebi et al., 2017; Forland et al., 2018).  457 
3. Conclusion 458 
Overall, the current study provides new insights regarding the molecular mechanisms 459 
governing the olfactory dysfunction occurring during PD progression. Besides the 460 
pathological depositions of α-synuclein occurring at the level of the OB, we have 461 
demonstrated a clear disarrangement in the olfactory proteostasis, affecting cell survival 462 
routes and showing potential common pathological substrates between PD and AD. 463 
Moreover, the application of high-throughput proteomic approaches again proves to be 464 
a useful tool to decipher the proteome expression profiles in olfactory structures and 465 
more importantly, to define potential fluid biomarkers for the diagnosis of 466 
neurodegenerative processes.  467 
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Figure and table legends 798 
Table 1. General characteristics of the subjects included in the study. LBDL: LBD-799 
limbic stage; LBDE: LBD-early-neocortical stage; LBDN: LBD-neocortical stage. 800 
Figure 1. MALDI imaging mass spectrometry of human OB. Mean spectra of the 801 
whole section of control OB (red) and each LTS stages (green), and the corresponding 802 
spatial distribution of the selected peaks. A) band at 1789 Th. B) band at 4205 Th. C) 803 
band at 2549 Th, and D) band at 15272 Th. This pattern can also be shown in the 804 
corresponding whisker-plots. 805 
Figure 2. OB Differentially proteins across PD-related phenotypes. A) Volcano 806 
plots from the pair-wise comparisons: control vs LBDL stage (upper panel), LBDE 807 
stage (middle panel), and LBDN stage (lower panel). Differential proteins: P < 0.01 in 808 
green, and P < 0.05 in yellow. B) OB monomeric α-synuclein expression. C) 809 
Differential olfactory proteome distributions. D) Common and unique differential 810 
proteins between LTS stages.  811 
Figure 3. Protein interactome maps for differentially expressed proteins in the OB 812 
during LTS progression. Visual representation of the relationships detected in LBDL 813 
(A), LBDE (B), and LBDN (C). Up-regulated proteins in red, and down-regulated 814 
proteins in green. Complete legend in 815 
http://ingenuity.force.com/ipa/articles/Feature_Description/Legend. 816 
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Figure 4. Monitoring of OB survival routes and specific protein intermediates 817 
across LTS grading. Levels and phosphorylation of MAP kinases (A), PDK1/PKC (B), 818 
MKK3-6/p38 MAPK (C), and AKT and CaMKII kinases (D) in the OB across PD 819 
phenotypes. CPNE6 and DPP6 protein expression levels across LTS stages (E). Protein 820 
variation in SCGN, CACYBP, GNPDA2, and RACK1 levels across PD phenotypes (F). 821 
*P < 0.05 vs control group; ** P < 0.01 vs control group; *** P < 0.01 vs control group. 822 
Statistical analysis between LTS stages is shown in additional file 9A. 823 
Figure 5. Monitoring of specific olfactory proteins during AD progression. 824 
GNPDA2 and α-synuclein levels in the CSF of PD subjects.  A) Protein levels of 825 
SCGN, CACYBP, GNPDA2, and RACK1 were monitored by Western-blotting across 826 
AD stages. Statistical analysis between AD stages is shown in additional file 9B. B) 827 
Inverse correlation between GNPDA2 and α-synuclein protein expression in CSF from 828 
PD subjects. *P < 0.05 vs control group; ** P < 0.01 vs control group; *** P < 0.01 vs 829 
control group.  830 
Figure 6. Serum GNPDA2 levels in PD population. GNPDA2 levels were measured 831 
in the sera derived from 164 individuals (82 controls; mean age: 69 years; 51M/31F and 832 
82 PD subjects: mean age: 67 years; 41M/41F) by ELISA (Mann–Whitney U test; p-833 
value: 0.0004). 834 
Additional material 835 
Additional file 1. General characteristics of the subjects included in the 836 
measurement of serum GNPDA2 levels 837 
Additional file 2. Olfactory proteomics. Differential expressed proteins between 838 
controls, and LTS staging (limbic, early-neocortical, and neocortical stages). 839 
Additional file 3. Functional analysis of common deregulated proteins across LTS 840 
stages. 841 
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Additional file 4. Functional analysis of deregulated OB proteome in each LTS stage. 842 
Additional file 5. Functional metrics of the differential OB proteome across LTS 843 
staging. A) Using Reactome database, differential OB proteomic expression profiles 844 
detected across LTS staging were mapped into regulatory pathways (See additional file 845 
4 for more details). B) Specific-neuronal functional categories for the differential OB 846 
proteomic expression profile detected in each LTS stage (See additional file 4 for more 847 
details). 848 
Additional file 6. Disease and biofunction analysis of differential OB proteomes. 849 
Additional file 7. CSF samples included in this study. 850 
Additional file 8. Traceability analysis across LTS proteomic datasets. 851 
Additional file 9. Monitoring of OB survival routes and specific olfactory proteins 852 
between PD and AD stages. Confirmation of the GNPDA2 overexpression in the OB of 853 
PD subjects (independent validation). 854 
 855 
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Case Age Sex Clinical Onset Duration PMI Neuropathological
diagnosis (years) (hours) diagnosis
Controls
C008 93 F 9 ageing-related changes
C048 68 M 10 micro-vascular pathology
C064 63 F 21 cerebellar infarcts
BK-0300 75 F 20 ARP I-II
BK-1378 78 M 6 leucoencephalopathy
BK-1078 84 F 6 Vascular encephalopathy
BK-1195 82 F 8 Acute stroke
BK-1485 79 M 5 Acute stroke 
PD
PD295 83 M PD 67 16 26 LBDL
PD340 67 M PD 53 14 12 LBDL
PD356 86 F PD 75 9 19 LBDL
PD541 72 M PD 66 6 11 LBDL
PD546 84 F PD 71 13 25 LBDL
PD579 76 M PD 55 21 9 LBDL
PD591 77 M PD 68 9 17 LBDL
PD275 79 M PD 65 15 22 LBDE
PD354 88 F PD 77 11 8 LBDE
PD423 66 F PD 53 13 19 LBDE
PD436 90 M PD 82 8 14 LBDE
PD520 80 M PD 56 24 22 LBDE
PD530 85 M PD 77 8 12 LBDE
PD357 71 M PD 37 34 15 LBDN
PD450 66 M PD 47 19 13 LBDN
PD495 88 F PD 61 28 25 LBDN
PD501 89 F PD 82 7 16 LBDN
PD537 84 M PD 84 9 18 LBDN
PD550 83 F PD 77 7 24 LBDN
PD562 79 M PD 72 7 16 LBDN
PD636 84 M PD 65 20 22 LBDN
AD
1452 70 M AD n.a n.a 3 Braak I
1370 79 F AD n.a n.a 10 Braak II
1429 78 F AD n.a n.a 3 Braak II
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1433 62 M AD n.a n.a 9 Braak II
1247 81 M AD n.a n.a 5 Braak III
1517 84 M AD n.a n.a 20 Braak III
1242 82 F AD n.a n.a 17 Braak IV
1248 84 M AD n.a n.a 12 Braak IV
1254 89 M AD n.a n.a 3 Braak IV
CS-1445 73 F AD 66 7 3 Braak VI
CS-0662 75 M AD 71 4 4 Braak VI
CS-0535 81 F AD 70 11 4 Braak VI
CS-0673 75 M AD 60 15 4 Braak VI
CS-1232 84 M AD 77 11 5 Braak VI
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Highlights 
• The proteomic profile of postmortem OBs across parkinsonian LTS stages was 
analyzed 
• Two hundred sixty eight proteins were deregulated across LTS staging of PD 
• Network-proteomics revealed cell survival signaling imbalance across LTS 
stages 
• Different expression of common olfactory substrates was observed between 
AD and PD.  
• Serum GNPDA2 levels were significantly decreased in PD population 
 
